Cargando…

Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases

Background: With the wide application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) patients with brain metastasis (BM) has been significantly improved. However, prognosis analysis for patients with EGFR mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xiaoqing, Fan, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603428/ https://www.ncbi.nlm.nih.gov/pubmed/31293653 http://dx.doi.org/10.7150/jca.30292

Ejemplares similares

Real‐world treatment and prognostic factors for survival in ALK+ non‐small cell lung cancer (NSCLC) patients with brain metastases in China
por: Li, Na, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
por: Wang, Haiyang, et al.
Publicado: (2018)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
por: Huang, Yu‐Chen, et al.
Publicado: (2018)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival
por: Rastogi, Kartick, et al.
Publicado: (2018)

Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
por: Yu, Xiaoqing, et al.
Publicado: (2019)

Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases
por: Ramotar, Matthew, et al.
Publicado: (2019)

Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
por: Linh, Do Mai, et al.
Publicado: (2023)

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
por: Wang, Zhenxin, et al.
Publicado: (2020)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
por: McGranahan, Tresa, et al.
Publicado: (2017)

Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
por: Qureshi, Samia, et al.
Publicado: (2022)

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
por: Yan, Weiwei, et al.
Publicado: (2019)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
por: Ton, Thanh G.N., et al.
Publicado: (2022)

Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Chen, Chien-Hung, et al.
Publicado: (2019)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Sheng, Jiamin, et al.
Publicado: (2021)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
por: Abernethy, Amy P., et al.
Publicado: (2017)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
por: Fan, Yun, et al.
Publicado: (2013)

The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status
por: Shao, Jun, et al.
Publicado: (2021)

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer
por: Piffko, Andras, et al.
Publicado: (2022)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs
por: Gui, Qi, et al.
Publicado: (2017)

Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data
por: Ito, Kentaro, et al.
Publicado: (2020)

Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival
por: Roszik, Jason, et al.
Publicado: (2022)

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases
por: Chang, JiaYu, et al.
Publicado: (2022)

Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice
por: Chen, Xin-Ru, et al.
Publicado: (2020)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
por: Bhandari, Shruti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9gjfkuplq3mdp0cg3utit7ri50